Influenza outbreaks in long-term-care facilities: How can we do better?

Infection Control and Hospital Epidemiology

Volumn 23, Issue 10, 2002, Pages 564-567

  Simor, Andrew E ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ATAXIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFUSION; DELIRIUM; DRUG EFFICACY; EDITORIAL; EPIDEMIC; HEALTH CARE FACILITY; HUMAN; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; LONG TERM CARE; NURSING HOME; RESIDENTIAL HOME; SEIZURE; VIRUS CULTURE;

EID: 0036794501     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/501971     Document Type: Editorial

References (58)

1. Lui K-J, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77:712-716.
2. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza on mortality: introducing a severity index. Am J Public Health 1997;87:1944-1950.
3. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2001;50(RR-4):1-46.
4. Goodman RA, Orenstein WA, Munro TF, Smith SC, Sikes K. Impact of influenza A in a nursing home. JAMA 1982;247:1451-1453.
5. Horman JT, Stetler HC, Israel E, Sorley D, Schipper MT, Joseph JM. An outbreak of influenza A in a nursing home. Am J Public Health 1986;76:501-504.
6. Meiklejohn G, Hall H. Unusual outbreak of influenza A in a Wyoming nursing home. J Am Geriatr Soc 1987;35:742-746.
7. Morens DM, Rash VM. Lessons from a nursing home outbreak of influenza A. Infect Control Hosp Epidemiol 1995;16:275-280.
8. Hall WN, Goodman RA, Noble GR, Kendal AP, Steece RS. An outbreak of influenza B in an elderly population. J Infect Dis 1981;144:297-302.
9. Simor AE, Sharpe S, Byrne S, Cruz T, McLaughlin B. Influenza B outbreak in a home for the aged, Ontario. Canada Diseases Weekly Report 1988;14:181-184.
10. Stevenson CG, McArthur MA, Naus M, Abraham E, McGeer AJ. Prevention of influenza and pneumococcal pneumonia in long-term care facilities: how are we doing? Canadian Medical Association Journal 2001;164:1413-1419.
11. Gravenstein S, Miller BA, Drinka P. Prevention and control of influenza A outbreaks in long-term care facilities. Infect Control Hosp Epidemiol 1992;13:49-54.
12. Gomolin IH, Leib HB, Arden NH, Sherman FT. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J Am Geriatr Soc 1995;43:71-74.
13. Bradley SF, the Long-Term-Care Committee of the Society for Healthcare Epidemiology of America. Prevention of influenza in long-term-care facilities. Infect Control Hosp Epidemiol 1999;20:629-637.
14. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985;253:1136-1139.
15. Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes: a case-control study. Am J Epidemiol 1986;124:114-119.
16. Meiklejohn G, Hoffman R, Graves P. Effectiveness of influenza vaccine when given during an outbreak of influenza A/H3N2 in a nursing home. J Am Geriatr Soc 1989;37:407-410.
17. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992;136:296-307.
18. McArthur MA, Simor AE, Campbell B, McGeer A. Influenza vaccination in long-term-care facilities: structuring programs for success. Infect Control Hosp Epidemiol 1999;20:499-503.
19. Arden NH. Control of influenza in the long-term-care facility: a review of established approaches and newer options. Infect Control Hosp Epidemiol 2000;21:59-64.
20. Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997;175:1-6.
21. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000;355:93-97.
22. Drinka PJ, Krause P, Nest L, Gravenstein S, Goodman B, Shult P. Delays in the application of outbreak control prophylaxis for influenza A in a nursing home. Infect Control Hosp Epidemiol 2002;23:600-603.
23. Hirji Z, O'Grady S, Bonham J, et al. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population. Infect Control Hosp Epidemiol 2002;23:604-608.
24. McGeer A, Campbell B, Emori TG, et al. Definitions of infection for surveillance in long-term care facilities. Am J Infect Control 1991;19:1-7.
25. Gravenstein S, Miller BA, Ershler WB, et al. Low sensitivity of CDC case definition for H3N2 influenza in elderly nursing home subjects. Clinical Research 1990;38:547A.
26. Taylor JL, Dwyer DM, Coffman T, Groves C, Patel J, Israel E. Nursing home outbreak of influenza A (H3N2): evaluation of vaccine efficacy and influenza case definitions. Infect Control Hosp Epidemiol 1992;13:93-97.
27. Simor AE, Augustin A, Staynor K, et al. Influenza A in elderly nursing home residents: evaluation of vaccine efficacy and case definitions of influenza-like illness. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17-20, 1993; New Orleans, LA. Abstract 1383.
28. Orr PH, Peeling RW, Fast M, et al. Serologic study of responses to selected pathogens causing respiratory tract infection in the institutionalized elderly. Clin Infect Dis 1996;23:1240-1245.
29. Waner JL, Todd SJ, Shalaby H, Murphy P, Wall LV. Comparison of Directigen FLU-A with viral isolation and direct immunofluorescence for the rapid detection and identification of influenza A virus. J Clin Microbiol 1991;29:479-482.
30. Leonardi GP, Leib H, Birkhead GS, Smith C, Costello P, Conron W. Comparison of rapid detection methods for influenza A virus and their value in health-care management of institutionalized geriatric patients. J Clin Microbiol 1994;32:70-74.
31. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med 1988;148:865-868.
32. Staynor K, Foster G, McArthur M, McGeer A, Petric M, Simor AE. Influenza A outbreak in a nursing home: the value of early diagnosis and the use of amantadine hydrochloride. Canadian Journal of Infection Control 1994;9:109-111.
33. Drinka PJ, Gravenstein S, Schilling M, Krause P, Miller BA, Shult P. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols. Arch Intern Med 1998;158:2155-2159.
34. Degelau J, Somani S, Cooper SL, Irvine PW. Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home. J Am Geriatr Soc 1990;38:428-432.
35. Stange KC, Little DW, Blatnik B. Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J Am Geriatr Soc 1991;39:700-705.
36. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000;160:1485-1488.
37. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991;134:988-997.
38. Degelau J, Somani SK, Cooper SL, Guay DRP, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992;152:390-392.
39. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use. Arch Intern Med 1995;155:533-537.
40. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000;21:700-704.
41. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997;337:874-880.
42. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877-1881.
43. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000;355:1845-1850.
44. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283:1016-1024.
45. Lalezari J, Campion K, Keene O, Silagyi C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001;161:212-217.
46. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31-35.
47. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-1343.
48. Hayden FG, Gubavera LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000;343:1282-1289.
49. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-754.
50. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs 1998;56:537-553.
51. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78-87.
52. Gubavera LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183:523-531.
53. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000;21:700-704.
54. McGeer AJ, Lee W, McArthur M, et al. Use of zanamivir to control an outbreak of influenza A in a nursing home. Clin Infect Dis 2000;31:318.
55. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002;50:608-616.
56. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001;49:1025-1031.
57. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998;16:1771-1774.
58. Gravenstein S, Drinka P, Osterweil D, et al. A multicenter prospective double-blind randomized controlled trial comparing the relative safety and efficacy of zanamivir to rimantadine for nursing home influenza outbreak control. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Ontario, Canada. Abstract 1155.